跳至主要内容
临床试验/NCT01029223
NCT01029223撤回4 期

The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals

Bayside Health0 个研究点目标入组 42 人开始时间: 2008年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
撤回
发起方
入组人数
42
主要终点
central and peripheral arterial and pulse wave velocity

研究概览

简要总结

The purpose of this study is to determine the effect of slowing heart rate upon both central and peripheral blood pressures using a medication called Ivabradine which slows heart rate without affecting heart contraction, and to compare the effects of ivabradine to a traditional blood pressure lowering medication called metoprolol (which is a beta-blocker).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Aged 18 - 25 years OR
  • Aged > 60 years
  • Exclusion Criteria
  • Chronic disease
  • Unable to give informed consent
  • Treated or untreated systemic arterial hypertension (SBP > 160 mmHg and/or DBP > 90 mmHg)
  • Resting bradycardia (heart rate < 60 beats/minute)
  • Pregnancy or active lactation

排除标准

  • 未提供

研究组 & 干预措施

ivabradine

Experimental

干预措施: ivabradine (Drug)

metoprolol

Experimental

干预措施: metoprolol (Drug)

placebo

Placebo Comparator

干预措施: placebo (Drug)

结局指标

主要结局

central and peripheral arterial and pulse wave velocity

时间窗: baseline, and 4 hours following the administration of placebo, metoprolol or ivabradine.

次要结局

  • Central pulse pressure(Baseline measurements of central and peripheral arterial and pulse wave velocity will be made at baseline, and 4 hours following the administration of either placebo, metoprolol or ivabradine.)

研究者

发起方
Bayside Health
申办方类型
Other Gov

相似试验